Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi

Journal of Clinical Investigation

Volumn 116, Issue 8, 2006, Pages 2201-2207

  Hafner, Christian ^a   Van Oers, Johanna M M ^b   Vogt, Thomas ^a   Landthaler, Michael ^a   Stoehr, Robert ^a   Blaszyk, Hagen ^c   Hofstaedter, Ferdinand ^a   Zwarthoff, Ellen C ^b   Hartmann, Arndt ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ACANTHOSIS NIGRICANS; ACHONDROPLASIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDERMIS; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MALE; MOSAICISM; NEVUS; POINT MUTATION; PRIORITY JOURNAL; THANATOPHORIC DWARFISM;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; CHILD; CHILD, PRESCHOOL; CODON; EPIDERMIS; FEMALE; HUMANS; INFANT; MALE; MOSAICISM; MUTATION; NEVUS; NEVUS, PIGMENTED; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SKIN NEOPLASMS;

EID: 33746754183     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28163     Document Type: Article

References (56)

1. Rothnagel, J.A., et al. 1992. Mutations in the rod domains of keratins 1 and 10 in epidermolytic hyperkeratosis. Science. 257:1128-1130.
2. Paller, A.S., et al. 1994. Genetic and clinical mosaicism in a type of epidermal nevus. N. Engl. J. Med. 331:1408-1415.
3. Konig, A., Happle, R., Bornholdt, D., Engel, H., and Grzeschik, K.H. 2000. Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am. J. Med. Genet. 90:339-346.
4. L'Hote, C.G., and Knowles, M.A. 2005. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. Cell Res. 304:417-431.
5. Scotet, E., and Houssaint, E. 1995. The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochim. Biophys. Acta. 1264:238-242.
6. Yokote, H., et al. 2005. Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc. Natl. Acad. Sci. U. S. A. 102:18866-18871.
7. Meyers, G.A., Orlow, S.J., Munro, I.R., Przylepa, K.A., and Jabs, E.W. 1995. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat. Genet. 11:462-464.
8. Muenke, M., et al. 1997. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am. J. Hum. Genet. 60:555-564.
9. Vajo, Z., Francomano, C.A., and Wilkin, D.J. 2000. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr. Rev. 21:23-39.
10. Baker, K.M., Olson, D.S., Harding, C.O., and Pauli, R.M. 1997. Long-term survival in typical thanatophoric dysplasia type 1. Am. J. Med. Genet. 70:427-436.
11. Webster, M.K., and Donoghue, D.J. 1997. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 13:178-182.
12. Tavormina, P.L., et al. 1995. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum. Mol. Genet. 4:2175-2177.
13. Tavormina, P.L., et al. 1995. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet. 9:321-328.
14. Rousseau, F., et al. 1996. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum. Mol. Genet. 5:509-512.
15. Naski, M.C., Wang, Q., Xu, J., and Ornitz, D.M. 1996. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 13:233-237.
16. d'Avis, P.Y., et al. 1998. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ. 9:71-78.
17. Watowich, S.S., et al. 1992. Homodimerization and constitutive activation of the erythropoietin receptor. Proc. Natl. Acad. Sci. U. S. A. 89:2140-2144.
18. Sorokin, A., Lemmon, M.A., Ullrich, A., and Schlessinger, J. 1994. Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond. J. Biol. Chem. 269:9752-9759.
19. Adar, R., Monsonego-Ornan, E., David, P., and Yayon, A. 2002. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J. Bone Miner. Res. 17:860-868.
20. Webster, M.K., and Donoghue, D.J. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15:520-527.
21. Li, E., You, M., and Hristova, K. 2006. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J. Mol. Biol. 356:600-612.
22. Lievens, P.M., Roncador, A., and Liboi, E. 2006. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2alpha and PLCgamma-independent pathways. J. Mol. Biol. 357:783-792.
23. Monsonego-Ornan, E., Adar, R., Feferman, T., Segev, O., and Yayon, A. 2000. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol. Cell. Biol. 20:516-522.
24. Lievens, P.M., Mutinelli, C., Baynes, D., and Liboi, E. 2004. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J. Biol. Chem. 279:43254-43260.
25. Bellus, G.A., et al. 2000. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am. J. Hum. Genet. 67:1411-1421.
26. Logie, A., et al. 2005. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet. 14:1153-1160.
27. Chesi, M., et al. 1997. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16:260-264.
28. van Rhijn, B.W., et al. 2002. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet. 10:819-824.
29. Cappellen, D., et al. 1999. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23:18-20.
30. Jang, J.H., Shin, K.H., and Park, J.G. 2001. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61:3541-3543.
31. Schwartz, R.A. 1994. Acanthosis nigricans. J. Am. Acad. Dermatol. 31:1-19; quiz 20-22.
32. Su, W.P. 1982. Histopathologic varieties of epidermal nevus. A study of 160 cases. Am. J. Dermatopathol. 4:161-170.
33. Happle, R. 1993. Mosaicism in human skin. Understanding the patterns and mechanisms. Arch. Dermatol. 129:1460-1470.
34. Happle, R. 1987. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J. Am. Acad. Dermatol. 16:899-906.
35. Curth, H.O. 1976. Unilateral epidermal naevus resembling acanthosis nigricans. Br. J. Dermatol. 95:433-436.
36. Kim, M.Y., Lee, J.S., Kim, H.O., and Park, Y.M. 2004. A case of nevoid acanthosis nigricans. Acta Derm. Venereol. 84:234-235.
37. Hyland, V.J., et al. 2003. Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. Am. J. Med. Genet. A. 120:157-168.
38. Rongioletti, F., and Rebora, A. 1991. Epidermal nevus with transitional cell carcinomas of the urinary tract. J. Am. Acad. Dermatol. 25:856-858.
39. Rosenthal, D., and Fretzin, D.F. 1986. Epidermal nevus syndrome: report of association with transitional cell carcinoma of the bladder. Pediatr. Dermatol. 3:455-458.
40. Garcia de Jalon, A., et al. 2004. Epidermal naevus syndrome (Solomon's syndrome) associated with bladder cancer in a 20-year-old female. Scand. J. Urol. Nephrol. 38:85-87.
41. Kimura, T., et al. 2001. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer. 92:2555-2561.
42. Van Esch, H., and Fryns, J.E. 2004. Acanthosis nigricans in a boy with achondroplasia due to the classical Gly380Arg mutation in FGFR3. Genet. Couns. 15:375-377.
43. Wilkie, A.O. 1997. Craniosynostosis: genes and mechanisms. Hum. Mol. Genet. 6:1647-1656.
44. Passos-Bueno, M.R., et al. 1999. Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat. 14:115-125.
45. Vujevich, J.J., and Mancini, A.J. 2004. The epidermal nevus syndromes: multisystem disorders. J. Am. Acad. Dermatol. 50:957-961.
46. Vidaurri-de la Cruz, H., Tamayo-Sanchez, L., Duran-McKinster, C., de la Luz Orozco-Covarrubias, M., and Ruiz-Maldonado, R. 2004. Epidermal nevus syndromes: clinical findings in 35 patients. Pediatr. Dermatol. 21:432-439.
47. Jebar, A.H., et al. 2005. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 24:5218-5225.
48. van Rhijn, B.W., et al. 2003. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. oncol. 21:1912-1921.
49. van Rhijn, B.W., Montironi, R., Zwarthoff, E.C., Jobsis, A.C., and van der Kwast, T.H. 2002. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 198:245-251.
50. Billerey, C., et al. 2001. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158:1955-1959.
51. Mohammadi, M., et al. 1997. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:955-960.
52. Trudel, S., et al. 2004. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood. 103:3521-3528.
53. Paterson, J.L., et al. 2004. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br. J. Haematol. 124:595-603.
54. Grand, E.K., Chase, A.J., Heath, C., Rahemtulla, A., and Cross, N.C. 2004. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 18:962-966.
55. Chen, J., et al. 2005. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 24:8259-8267.
56. van Oers, J.M., et al. 2005. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin. Cancer Res. 11:7743-7748.